Data Monitoring Committees play a vital role in safeguarding patient safety and supporting informed decision-making throughout clinical development, particularly in rare disease studies where every data point matters.
In this ALS clinical trial, Phastar provided independent statistical support for four periodic safety reviews and a formal interim analysis, delivering validated outputs, secure reporting processes, and experienced DMC leadership.
Through careful management of blinded and unblinded activities, robust statistical programming, and responsive support for emerging safety questions, the team helped ensure effective trial oversight and reliable decision-making.
Download the full case study to see how Phastar supports safety monitoring, interim analyses, and independent data review in rare disease clinical trials.